...
首页> 外文期刊>Pharmacology: International Journal of Experimental and Clinical Pharmacology >Wogonoside Inhibits Prostate Cancer Cell Growth and Metastasis via Regulating Wnt/beta-Catenin Pathway and Epithelial-Mesenchymal Transition
【24h】

Wogonoside Inhibits Prostate Cancer Cell Growth and Metastasis via Regulating Wnt/beta-Catenin Pathway and Epithelial-Mesenchymal Transition

机译:通过调节WNT /β-连环蛋白途径和上皮间充质转换,Wongonoside抑制前列腺癌细胞生长和转移

获取原文
获取原文并翻译 | 示例

摘要

Background: Wogonoside, an effective component of Scutellaria baicalensis extract, has recently become a hot topic for its newly discovered anticancer efficacy, but the underlying pharmacological mechanism is still unclear. In this study, we tested the inhibitory effects of wogonoside in human prostate cancer PC3 cells in vitro and vivo. Methods: The effects of wogonoside on cell viability, cycle progression, invasion, migration, and apoptosis were assessed in vitro. The levels of proteins in related signaling pathways were detected by western blotting assay. Finally, nude mouse tumorigenicity assay was conducted to detect the anticancer effect of wogonoside in vivo. Results: Wogonoside inhibited cell viability, invasive and migratory ability in a time- and dose-dependent manner. Flow cytometry indicated that wogonoside could induce cell apoptosis and S phase cell-cycle arrest. Mechanically, wogonoside suppressed the Wnt/beta-catenin signaling pathway, and the level of p-glycogen synthase kinase-3 beta (GSK-3 beta; Ser(9)) was inhibited by wogonoside. The epithelial-mesenchymal transition (EMT) process was also reversed in PC3 cell line after wogonoside treatment. In vivo experiments showed that wogonoside inhibited tumor growth in xenograft mouse models. Conclusion: These findings revealed that wogonoside could suppress Wnt/beta-catenin pathway and reversing the EMT process in PC3 cells. GSK-3 beta acts as a tumor suppressor in prostate cancer. Wogonoside may serve as an effective agent for treating prostate cancer.
机译:背景:Wogonoside是Scutellaria Baicalensis提取物的有效组成部分,最近成为新发现的抗癌疗效的热门话题,但潜在的药理学机制仍然尚不清楚。在这项研究中,我们测试了Wogonoside在体外和体内人前列腺癌PC3细胞中的抑制作用。方法:在体外评估Wogonoside对细胞活力,循环进程,侵袭,迁移和细胞凋亡的影响。通过蛋白质印迹测定检测相关信号传导途径中的蛋白质水平。最后,进行了裸鼠瘤状测定以检测Wogonoside在体内的抗癌作用。结果:Wogonoside以时间和剂量依赖的方式抑制细胞活力,侵入性和迁移能力。流式细胞术表明,Wogonoside可以诱导细胞凋亡和S期细胞周期停滞。机械地,WOGONOSIDE抑制了WNT /β - catenin信号传导途径,并通过WOGONOSIDE抑制了P-糖原合酶激酶-3β(GSK-3β; SER(9))的水平。在Wogonoside治疗后,上皮 - 间充质过渡(EMT)过程也在PC3细胞系中逆转。体内实验表明,Wogonoside抑制了异种移植小鼠模型中的肿瘤生长。结论:这些发现显示,WOGONOSIDE可以抑制WNT /β-连环蛋白途径并在PC3细胞中逆转EMT过程。 GSK-3β作为前列腺癌中的肿瘤抑制作用。 Wogonoside可以作为治疗前列腺癌的有效剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号